Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A

被引:0
作者
Pezzilli, R
Migliori, M
Morselli-Labate, AM
Campana, D
Ventrucci, M
Tomassetti, P
Corinaldesi, R
机构
[1] Univ Bologna, Dipartimento Med Interna & Gastroenterol, Osped Sant Orsola, I-40138 Bologna, Italy
[2] Hosp Bentivoglio, Dept Internal Med, Bologna, Italy
关键词
chromogranins; diagnostic techniques and procedures; isoenzymes; neuroendocrine tumors; pyruvate kinase;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: M2-pyruvate kinase isoenzyme (M2-PK) is expressed by undifferentiated or proliferating tissue. The aim of the study was to establish the diagnostic role of tumor M2-PK (TM2-PK) in patients with neuroendocrine tumors and to compare its diagnostic value with that of chromogranin A (CgA) which is well-established. Materials and Methods: Forty-nine patients with proven neuroendocrine tumors were divided as follows: subgroup A (17 patients in whom the tumor was surgically removed), subgroup B (9 patients with the neoplasm without metastases) and subgroup C (23 patients with tumor and distant metastases). Twenty-four healthy subjects were also studied as controls. Plasma TM2-PK and CgA were measured using ELISA techniques. Results: TM2-PK concentrations (cut-off value 5.6 U/mL) were abnormally high in 25.0% of the healthy subjects, in 41.2% of the patients of subgroup A, in 66.7% of those of subgroup B and in 78.3% of those of subgroup C. CgA concentrations (cut-off value 5.0 U/L) were normal in all healthy subjects, whereas they were abnormally high in 76.5% of the patients of subgroup A, in 88.9% of those of subgroup B and in 95.7% of those of subgroup C. Conclusion: Since TM2-PK has a sensitivity similar to that of CgA while its specificity is significantly lower (p=0.031), it seems. of limited value in detecting neuroendocrine tumors.
引用
收藏
页码:2969 / 2972
页数:4
相关论文
共 19 条
[1]   Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].
Brandi, ML ;
Gagel, RF ;
Angeli, A ;
Bilezikian, JP ;
Beck-Peccoz, P ;
Bordi, C ;
Conte-Devolx, B ;
Falchetti, A ;
Gheri, RG ;
Libroia, A ;
Lips, CJM ;
Lombardi, G ;
Mannelli, M ;
Pacini, F ;
Pondder, BAJ ;
Raue, F ;
Skogseid, B ;
Tamburrano, G ;
Thakker, RV ;
Thompson, NW ;
Tomassetti, P ;
Tonelli, F ;
Wells, SA ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671
[2]  
BRINCK U, 1994, VIRCHOWS ARCH, V424, P177
[3]  
Cerwenka H, 1999, ANTICANCER RES, V19, P849
[4]  
EIGENBRODT E, 1992, Critical Reviews in Oncogenesis, V3, P91
[5]  
Eigenbrodt E, 1997, ANTICANCER RES, V17, P3153
[6]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[7]  
IBSEN KH, 1982, CANCER RES, V42, P888
[8]  
Lüftner D, 2000, ANTICANCER RES, V20, P5077
[9]   Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones [J].
Nobels, FRE ;
Kwekkeboom, DJ ;
Coopmans, W ;
Schoenmakers, CHH ;
Lindemans, J ;
DeHerder, WW ;
Krenning, EP ;
Bouillon, R ;
Lamberts, SWJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (08) :2622-2628
[10]  
NORUSIS MJ, 1992, SPSS PC PLUS BASE SY